New drug cocktails tested for tough colorectal cancer
NCT ID NCT04294160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested several drug combinations in 122 adults with advanced or metastatic BRAF V600 colorectal cancer. The goal was to find safe doses and understand side effects. The trial was terminated, so final results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dabrafenib, Trametinib, LTT462, LXH254, TNO155, Spartalizumab, Tislelizumab
- What this could lead to
- If successful, this could help identify safer and more effective drug combinations for treating advanced BRAF V600 colorectal cancer.
- What could go wrong
- This was a very early (Phase 1) study that was terminated, so results are limited. The combinations may not work better than existing treatments and could have significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600 COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Brussels, 1000, Belgium
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Zoetermeer, NL-2722 EP, Netherlands
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Valencia, Valencia, 46010, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sarah Cannon Research Institute SC
Nashville, Tennessee, 37203, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of California LA Santa Monica Location
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.